Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Archemix and Dicerna to collaborate on conjugated aptamer-dicer substrate RNAi therapeutics
August 2009
SHARING OPTIONS:

CAMBRIDGE, Mass.—Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, and Dicerna Pharmaceuticals Inc., a second-generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and dicer substrate RNA (DsiRNA) molecules, announced in July that the two companies will collaborate on aptamer-DsiRNA therapeutics that leverage both the intracellular delivery capabilities of Archemix's aptamers and the gene silencing of Dicerna's DsiRNA molecules. The agreement includes an option for Dicerna to obtain exclusive rights to further develop and commercialize aptamer-DsiRNA therapeutics generated during the collaboration. Additional terms of the agreement were not disclosed. 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.